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Original Contribution

Safety and Efficacy of Drug-Eluting Balloons in the Treatment
of Drug-Eluting In-Stent Restenosis: Experience of a
Tertiary Care Hospital
Sajid Dhakam, MD1, Asif Jafferani, MBBS2, Hafeez Ahmed, MBBS1, Nasir Rahman, MBBS1, Ambreen Gowani, BScN1
tested favorably in preclinical studies, with adequate delivery of drug from balloon (~90% in 1 minute of inflation), 1
and significant reduction in areas of neointimal proliferation,1,5,6 diameter stenosis, and late luminal loss. 7 Clinical
studies following them are limited; however, they clearly
demonstrate a favorable reduction in late luminal loss,
restenosis rates, and major adverse cardiovascular events
(MACE) in de novo8 and bifurcation lesions.9 However,
their efficacy in lesions with in-stent restenosis (ISR) is the
most promising,10,11 and as such, needs further research to
define the adequate place of the DEB in the interventionalist’s armament. 12 Hence, this registry aims to determine
the safety and efficacy of the use of DEBs in patients with
drug-eluting ISR at a tertiary care hospital in Pakistan.
The SeQuent Please DEB (B. Braun) was used primarily in this study. It is a coated balloon delivering paclitaxel
directly to the lesion site. Paclitaxel 3 µg/mm 3 is embedded
in a hydrophilic, bioabsorbable matrix which, after balloon
deflation, adheres to the vessel wall to allow prolonged
drug delivery to the lesion site.4
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Abstract: Background. The advent of drug-eluting balloons (DEBs) is a promising development for coronary revascularization procedures, especially for in-stent restenosis (ISR).
This study aims to highlight our experience with DEBs in the
treatment of drug-eluting ISR at a tertiary care hospital in Pakistan. Methods. All patients presenting to our institution from
August 2008 to February 2011 with significant drug-eluting instent restenosis (DES-ISR) who were eligible to receive treatment
via DEB were included in the analysis. Patient baseline characteristics and angiographic data about the lesion characteristics were
obtained. Postprocedural and follow-up endpoints, including cardiac death, myocardial infarction, and repeat revascularization,
ie, major adverse cardiovascular events (MACE), were included
in the analysis. Results. A total of 26 patients received treatment
with DEB in the study period, with a significant number having
major predisposing factors for the development of ischemic heart
disease (IHD; 46% diabetics; 92% hypertensives). The culprit
lesion was most commonly identified in the left anterior descending (31%), with presence of American College of Cardiology/
American Heart Association lesion type C in 68% of patients.
The SeQuent Please paclitaxel-eluting balloon (B. Braun) was
used for revascularization. Patients were followed for a median of
16 months. Only 5 patients (19%) developed MACE during this
period. Conclusion. Our experience demonstrates the effectiveness of DEBs in the treatment of drug-eluting ISR, especially in
complex lesions with patients having significant risk factors for
development of IHD. However, further studies are needed to define their indications in this role.
J INVASIVE CARDIOL 2012;24(7):335-338
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The drug-eluting balloon (DEB) was designed1 to address the incumbent issues of neointimal proliferation and
stent thrombosis, which are the banes of the established
technology of the bare-metal stent (BMS) and drug-eluting
stent (DES). 2,3 Theoretically, this device could deliver the
drug evenly to the vessel wall, limiting neointimal proliferation and at the same time reducing dependency on longterm anti-platelet therapy for vessel patency.4 This concept
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Methods

Registry setup. The Aga Khan University Hospital
(AKUH) in Karachi is a major tertiary care hospital serving
more than 10 million people of Karachi and the surrounding region. 13 The registry was approved by the Institution’s
Ethics Review Committee. The registry did not receive any
external funding. All the patients gave written informed
consent for the procedure.
Inclusion/exclusion criteria. All patients who presented to
our Institute during the period from August 2008 to February
2011 with angiographic evidence of >50% luminal diameter stenosis ISR with clinical or imaging evidence of ischemia, or >70%
luminal narrowing of ISR in the absence of evidence of ischemia
in their prior implanted DES, who subsequently underwent
treatment with DEB were included. Patients with narrowing in
the prior balloon only treated segments were excluded.
Procedural details. All patients received 300 mg aspirin and 300 mg clopidogrel 6 hours preprocedure and had
intravenous heparin administered to maintain activated
clotting time at >250 seconds during the procedure. Administration of glycoprotein IIb/IIIa inhibitors was left to
the physician’s discretion.
Technique. A lesion deemed sutiable for treatment with
DEB was first prepared with either a compliant or a non335
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Table 1. Patient characteristics with those having DES-ISR.
Characteristic

Patients
(n = 26)

Age (years)

65.69 ± 12.74

Male

21 (80.8%)

Diabetic

12 (46.2%)

Hypertensive

24 (92.3%)

Dyslipidemic

7 (31.8%)

Chronic kidney disease

4 (18.2%)

Data given as mean ± standard deviation or mean (percentage).
Table 2. Morphology and lesion characteristics of patients
with ISR treated with DEB.
Characteristic

n = 26
12 (46.2%)

Ostial target lesion

4 (15.4%)

Bifurcation lesion
Intracoronary thrombus
Severe tortuosity
Coronary artery disease
Single-vessel disease
2-vessel disease
3-vessel disease
Treated vessel
Right coronary artery
Left circumflex
Left anterior descending
Saphenous vein graft
Left main
Obtuse marginal
Diagonal
Stenosis (%)
Mean lesion length (mm)

C

Evidence of calcification
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Vessel diffusely diseased

5 (19.2%)

Results

14 (53.8%)

A total of 26 patients with DES-ISR underwent revascularization using DEB during the study period. Baseline
patient characteristics of those having ISR are given in
Table 1. Hypertension and diabetes were identified as important risk factors.
Most patients had more than 1 diseased vessel and the
target vessel most frequently revascularized was the left
anterior descending (LAD) artery. Morphology and lesion
characteristics are given in Table 2, while procedure-related
details of the DEB used are given in Table 3. No patient
required stenting at the lesion treated with DEB.
In-hospital results. No acute postprocedural complications were observed, including no-reflow and dissection.
During the hospital stay, 1 patient developed cardiogenic
shock and died. No other patients developed MACE; however, 4 patients still had angina symptoms and were managed medically.
Follow-up results. Patients were followed for a median
of 16 months; during this time, 8 patients continued to remain symptomatic, of which 4 patients developed MACE,
with 1 presumed cardiac death and 3 revascularizations.
Therefore, the total MACE rate was 19%. There were also
2 deaths due to proven non-cardiac causes in the followup period; 1 with epidural tuberculous abscess and 1 secondary to cerebral hemorrhage almost 1.5 years after the
procedure. The remaining patients considered symptomatic had complaints of chest discomfort, with no objective
evidence for the presence of ischemia or MI. Details of the
above, including MACE rates, are given in Table 4.

2 (7.7%)

4 (15.4%)
5 (20.8%)
8 (33.3%)

11 (45.8%)
6 (23.1%)
7 (26.9%)
8 (30.8%)
2 (7.7%)
1 (3.8%)
1 (3.8%)
1 (3.8%)

91.92 ± 9.52

25.63 ± 11.97

Lesion type
A

0 (0%)

B1

3 (12%)

B2

5 (20%)

C

17 (68%)

Vessel diameter (mm)

3 ± 0.24*

Data given as numbers (percentages), mean ± standard deviation, or
*
median ± interquartile range.

compliant balloon as per requirement to fully expand the
lesion in order to achieve its maximal luminal diameter,
according to the reference vessel diameter. DEB was used
336

as the last step for the lesion treatment with no further ballooning done after DEB to ensure maximum availability of
the drug delivered to the vessel wall. The balloon-to-artery
ratio for the study subjects was kept at 0.9:1. The DEB
was inflated at the site of ISR for 60 seconds at its nominal
pressure. If the lesion length was large and such a size was
not available, then two short-length DEBs were used sequentially to completely cover the lesion. Angioplasty was
considered adequate at <20% residual stenosis.
Follow-up and endpoints. All patients were followed in
the clinic post discharge. MACE included all postprocedural
cardiac deaths, myocardial infarctions (MIs), and need for repeat revascularization.
Statistical analysis. Statistical analysis was carried out
using SPSS version 17.0 (SPSS Inc). Continuous variables
were presented as mean ± standard deviation (SD) or median ± interquartile range (IQR) and categorical variables
were presented as numbers (percentages). No confirmatory
analysis was performed.

Discussion
DEB development has been one of the most promising
approaches for the treatment of ISR lesions. In the first
clinical study for DEB, the PACCOCATH ISR I trial, the
paclitaxel-eluting balloon was compared with an uncoated
balloon for the treatment of coronary ISR. Six-month postThe Journal of Invasive Cardiology®

DES to Treat In-Stent DES Restenosis: Experience of a Tertiary Care Hospital
Table 3. Procedural details of DEB use in ISR.
Procedure

n = 26

Balloon size x length (mm)
2.5 x 17

2

2.5 x 26

2

2.75 x 20

1

3.0 x 17

1

3.0 x 20

3

3.0 x 26

5

3.0 x 30

5

3.25 x 26

1

3.25 x 30

1

3.5 x 26

2

3.5 x 30

3

Residual stenosis (%)

11.54 ± 9.25
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Data given as numbers or mean ± standard deviation.

Table 4. Complications in patients undergoing revascularization with DEB.
Complication

Bleeding
Angina symptoms
Postprocedural mortality
Cardiac
Non-cardiac
CABG required
RePTCA required

In-Hospital
Rates
(n = 26)

At
Follow-up
(n = 25)

1 (3.8%)

—

4 (15.4%)

8 (32%)

1 (3.8%)
—

1 (4%)
2 (8%)

—

3 (12%)

—

CABG = coronary artery bypass graft; PTCA = percutaneous
transluminal coronary angioplasty.

angiography follow-up showed a significantly decreased late
lumen loss in the coated balloon groups.10 Results of the
PACCOCATH ISR I and II trials, both of which had identical protocols, were pooled to get a larger sample size and
longer follow-up period. These results further confirmed the
previous, with lower rates for binary restenosis and MACE
in the coated-balloon group until 2 years.11
However, the real question remained about the relative efficacy and safety of the DEB as compared to the DES, which
is the standard of care in lesions with ISR. This was answered
in the PEPCAD II trial, comparing the SeQuent Please paclitaxel-eluting balloon with a paclitaxel-eluting stent (Taxus
Liberté) in lesions with ISR. At 6-month follow-up, the trial
showed a lower late lumen loss in the DEB group, with lower
binary restenosis rates.14 Thus, the DEB was at least as safe
and efficacious as the DES in patients with ISR.
It must be remembered that while the PEPCAD II trial enrolled patients with ISR in BMS,14 data are still accumulating
Vol. 24, No. 7, July 2012

on the role of DEB in DES-ISR. It is well known that ISR
occurring in DES is more difficult to treat, with further DES
in this situation also having higher MACE and revascularization rates.15-17 A recent report by Raja et al demonstrates their
experience in the use of SeQuent Please DEB in the treatment
of DES-ISR for bifurcating lesions.18 Further experience comes
for another DEB technology with the Dior (Eurocor), which
was evaluated by a Spanish multicenter registry evaluating
1-year outcomes for ISR in both BMS as well as DES.19 Results
were favorable in both groups, with a MACE rate of 16.7%;
however, the DES group had a non-significant trend toward
higher MACE at 1 year. In the same vein, a larger multicenter
registry published their data on the use of the Dior in ISR lesions in BMS as well as DES.20 Their results also demonstrated
a favorable cumulative MACE rate of 11.5% at 7.5 months
follow-up. Recent studies on the SeQuent Please include the
PEPCAD-DES, and data from this trial reported at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 conference
showed the SeQuent Please to be superior to plain old balloon
angioplasty in preventing late lumen loss (0.43 ± 0.61 mm vs
1.03 ± 0.77 mm, respectively; P<.001) and binary restenosis
(17.2% vs 58.1%, respectively; P<.001) in DES-ISR lesions at
6-month angiographic follow-up.21
As this is a relatively new technology, DEBs have not
been adequately evaluated in different patient populations
with different risks and baseline characteristics. Of note is
the fact that in this registry, there was a significantly larger
number of patients with diabetes as compared to the patient
populations enrolled in the previously discussed trials. Diabetes is known to be a risk factor for developing ISR,19,22,23
and results from this study support the fact that the DEB
prevents development of binary restenosis in patients with
diabetes, among other cardiovascular risk factors. Furthermore, patients had fairly complex lesions and this may have
resulted in the slightly higher rate for MACE as compared
to those reported in other registries.
Study limitations. This study has several limitations
that must be taken into account. The registry size was relatively small; thus, it may not reflect all the ramifications
of treatment with DEB for such patients. However, since
research into the role of DEBs in treating DES-ISR lesions
is still in its infancy, it remains for designed well-powered
trials to truly establish its role for this indication. Also,
our patients did not undergo follow-up angiography to
determine if the procedure had remained successful and
thus, those who presented with mortality may not actually
have the DEB-treated lesion as the culprit for MACE. This
follow-up was, however, beyond the resources of this study.

Conclusion
The DEB appears to be a promising technology for ISR,
especially of the DES. Our experience, however, illustrates
the need for further evidence in terms of randomized trials
in different patient populations with results stratified to
take into account established risk factors for ISR, and further elucidation of patient characteristics of those developing MACEs and mortality after the DEB procedure, before
337

DHAKAM, et al.

its indications can be better identified to serve the patient
population at large.
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